Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Age and Comorbidities on Treatment Outcomes of First-line Treatment With Palbociclib in Combination With an Aromatase Inhibitor (AI) in Patients Diagnosed With HR+/HER2 - Metastatic Breast Cancer - Danish Non-Interventional Study

NCT06307457 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06307457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06307457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Age and Comorbidities on Treatment Outcomes of First-line Treatment With Palbociclib in Combination With an Aromatase Inhibitor (AI) in Patients Diagnosed With HR+/HER2 - Metastatic Breast Cancer - Danish Non-Interventional Study
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
March 6, 2024
Completion date
April 19, 2024
Enrollment
604 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer